<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01229930</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000687338</org_study_id>
    <secondary_id>CRUK-C-2009-01</secondary_id>
    <secondary_id>EUDRACT-2009-011542-25</secondary_id>
    <secondary_id>ISRCTN-23516549</secondary_id>
    <secondary_id>EU-21080</secondary_id>
    <secondary_id>ZENECA-CRUK-C-2009-01</secondary_id>
    <nct_id>NCT01229930</nct_id>
  </id_info>
  <brief_title>Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>CIRCCa - A Randomized Double Blind Phase II Trial of Carboplatin-Paclitaxel Plus Cediranib Versus Carboplatin-Paclitaxel Plus Placebo in Metastatic/Recurrent Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Cediranib maleate may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known&#xD;
      whether carboplatin and paclitaxel are more effective when given with or without cediranib&#xD;
      maleate in treating patients with cervical cancer that cannot be removed by surgery.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving carboplatin and paclitaxel&#xD;
      together with cediranib maleate to see how well it works compared with giving carboplatin and&#xD;
      paclitaxel together with a placebo in treating patients with metastatic or recurrent cervical&#xD;
      cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To provide preliminary evidence regarding whether the addition of cediranib maleate to a&#xD;
           combination of carboplatin and paclitaxel will increase the progression-free survival by&#xD;
           50% from 4 to 6 months in patients with metastatic or recurrent, undetectable cervical&#xD;
           carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To provide estimates of differences in response, survival, toxicity, quality of life,&#xD;
           and pharmacodynamic end-points between the study arms.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3 hours&#xD;
           on day 1. Patients also receive oral placebo once daily.&#xD;
&#xD;
        -  Arm II: Patients receive carboplatin and paclitaxel therapy as in Arm I. Patients also&#xD;
           receive oral cediranib maleate once daily.&#xD;
&#xD;
      In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients with complete response, partial response, or&#xD;
      stable disease following completion of therapy receive cediranib maleate or placebo until&#xD;
      evidence of progression or toxicity.&#xD;
&#xD;
      Blood samples may be collected periodically for evaluation of the VEGFR signaling inhibitor&#xD;
      cediranib maleate and identification of suitable biomarkers that predict cediranib maleate&#xD;
      response. Quality-of-life is assessed by the EORTC QLQ-C30 and QLQ-CX24 cervix subscale&#xD;
      questionnaires at baseline and periodically during study and follow up.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 2 months for 3 years, every&#xD;
      6 months for 2 years, and then annually thereafter.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in plasma VEGFR2 levels from baseline to day 28</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to chemotherapy using RECIST1.1 criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessed using NCI CTCAE v4.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed using EORTC QLQ-C30 and CX24</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cervical Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed carcinoma of the cervix, including any of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Squamous cell carcinoma&#xD;
&#xD;
               -  Adenocarcinoma&#xD;
&#xD;
               -  Adenosquamous cell carcinoma&#xD;
&#xD;
          -  Must meet one of the following criteria:&#xD;
&#xD;
               -  Persistent or relapsed inoperable disease after radical radiotherapy within the&#xD;
                  irradiated pelvis&#xD;
&#xD;
               -  Relapse after radical hysterectomy (after radical radiotherapy to pelvis, if&#xD;
                  appropriate)&#xD;
&#xD;
               -  Extra pelvic metastases&#xD;
&#xD;
               -  Primary stage IVB disease&#xD;
&#xD;
          -  Not suitable for potentially curative surgical procedure&#xD;
&#xD;
          -  Measurable disease in ≥ 1 marker site&#xD;
&#xD;
          -  No CNS disease, including brain metastases, within the past 6 months&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 35 mL/min&#xD;
&#xD;
          -  No proteinuria &gt; 1+ on dipstick (on 2 consecutive dipsticks not less than 1 week&#xD;
             apart), unless urinary protein is &lt; 1.5 g in a 24-hour period&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT or AST ≤ 2.5 times ULN (≤ 5 times ULN if hepatic metastases present)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN if hepatic metastases present)&#xD;
&#xD;
          -  Prothrombin ratio (PTR)/INR ≤ 1.5 OR PTR/INR 2.0-3.0 for patients on stable dose of&#xD;
             anticoagulant&#xD;
&#xD;
          -  Partial thromboplastin time &lt; 1.2 times control&#xD;
&#xD;
          -  No history of a nervous or psychiatric disorder that would prevent informed consent&#xD;
             and compliance&#xD;
&#xD;
          -  No prior malignancy within the past 5 years, except for successfully treated basal&#xD;
             cell skin cancer or in-situ breast cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No uncontrolled infection, defined as infection that cannot be resolved readily with&#xD;
             antibiotics prior to trial entry&#xD;
&#xD;
          -  No history of significant gastrointestinal impairment, as judged by the Investigator,&#xD;
             that would significantly affect the absorption of cediranib maleate&#xD;
&#xD;
          -  No history of pelvic fistula&#xD;
&#xD;
          -  No history of inflammatory bowel disease&#xD;
&#xD;
          -  No sub-acute or acute intestinal obstruction&#xD;
&#xD;
          -  No significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No active bleeding&#xD;
&#xD;
          -  No history or evidence of thrombotic or hemorrhagic disorders&#xD;
&#xD;
          -  No uncontrolled seizures, cerebrovascular accident, transient ischemic attack, or&#xD;
             subarachnoid hemorrhage within the past 6 months&#xD;
&#xD;
          -  No significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Arterial thrombotic event within the past 12 months&#xD;
&#xD;
               -  Angina within the past 6 months&#xD;
&#xD;
               -  History of poorly controlled or uncontrolled hypertension or resting BP &gt; 150/100&#xD;
                  mm Hg in the presence or absence of a stable regimen of anti-hypertensive therapy&#xD;
                  within the past 6 months&#xD;
&#xD;
               -  NYHA class II-IV congestive heart failure&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade 3 or cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Prolonged QTc (corrected) interval of &gt; 470 ms on ECG or a family history of long&#xD;
                  QT syndrome&#xD;
&#xD;
          -  Patients with rate-controlled atrial fibrillation are eligible&#xD;
&#xD;
          -  Not requiring intravenous nutritional support&#xD;
&#xD;
          -  No preexisting sensory or motor neuropathy ≥ grade 2&#xD;
&#xD;
          -  No history or clinical suspicion of spinal cord compression&#xD;
&#xD;
          -  No known hypersensitivity to carboplatin or paclitaxel&#xD;
&#xD;
          -  No evidence of any other disease, metabolic dysfunction, physical examination finding,&#xD;
             or laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or puts the patient at high risk&#xD;
             for treatment-related complications&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No unresolved toxicity ≥ CTC grade 2 from prior systemic anti-cancer therapy, except&#xD;
             hematological toxicity or alopecia&#xD;
&#xD;
          -  No prior chemotherapy, except cisplatin administered along with radiotherapy as&#xD;
             primary treatment&#xD;
&#xD;
          -  No major surgery within 28 days or anticipated while on study&#xD;
&#xD;
          -  More than 2 weeks since prior and no concurrent potent inhibitors of CYP3A4 and 2C8,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Amiodarone&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Simvastatin&#xD;
&#xD;
               -  Atorvastatin&#xD;
&#xD;
               -  Lovastatin&#xD;
&#xD;
               -  Montelukast sodium&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Miconazole&#xD;
&#xD;
               -  Indinavir (and other antivirals)&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
          -  No concurrent grapefruit juice or St. John wort&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Paul Symonds, MD, FRCP, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals, Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE19 4LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK and University College London Cancer Trials Centre</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1T 4TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2010</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>cervical adenocarcinoma</keyword>
  <keyword>cervical adenosquamous cell carcinoma</keyword>
  <keyword>cervical squamous cell carcinoma</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

